Nicoletta Loggia
Chief Tech/Sci/R&D Officer at ORCHARD THERAPEUTICS PLC
Net worth: - $ as of 2024-04-29
Profile
Nicoletta Loggia is an Independent Director at Candel Therapeutics, Inc. and the Chief Technical Officer at Orchard Therapeutics Plc.
She holds a doctorate degree from the University of Pavia.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-03-31 | 0 ( -.--% ) | - $ | 2024-04-29 |
Nicoletta Loggia active positions
| Companies | Position | Start |
|---|---|---|
| ORCHARD THERAPEUTICS PLC | Chief Tech/Sci/R&D Officer | 2021-09-08 |
| CANDEL THERAPEUTICS, INC. | Director/Board Member | 2023-06-06 |
Training of Nicoletta Loggia
| University of Pavia | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| CANDEL THERAPEUTICS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Nicoletta Loggia